Giulia Sbianchi

Melphalan 140 mg/m ² or 200 mg/m ² for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

Holger W. Auner, Simona Iacobelli, Giulia Sbianchi et al. · Haematologica · 2017 · 87 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

Nicolaus Kröger, Giulia Sbianchi, Tiarlan Sirait et al. · Leukemia · 2021 · 74 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Impact of T‐cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party

Sujith Samarasinghe, Katherine Clesham, Simona Iacobelli et al. · American Journal of Hematology · 2018 · 27 citations · Full text

Medicine, Hematology, Immunology +17

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the <scp>EBMT</scp>

Yves Chalandon, Giulia Sbianchi, Luuk Gras et al. · American Journal of Hematology · 2022 · 20 citations · Full text

Medicine, Hematology, Pharmacotherapy +8

Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study

Anna Waszczuk‐Gajda, Olaf Penack, Giulia Sbianchi et al. · Journal of Clinical Medicine · 2022 · 18 citations · Full text

Medicine, Hematology, Oncology +17